Log in

NASDAQ:BTAIBioXcel Therapeutics Stock Price, Forecast & News

$46.56
+3.56 (+8.28 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$41.27
Now: $46.56
$47.39
50-Day Range
$21.31
MA: $36.57
$50.30
52-Week Range
$3.76
Now: $46.56
$51.83
Volume693,966 shs
Average Volume407,339 shs
Market Capitalization$940.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
BioXcel Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
CUSIPN/A
Phone475-238-6837

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.59 per share

Profitability

Net Income$-32,970,000.00

Miscellaneous

Employees18
Market Cap$940.98 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

How has BioXcel Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BTAI shares have increased by 57.9% and is now trading at $46.56. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioXcel Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioXcel Therapeutics.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for BioXcel Therapeutics.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) posted its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.21. View BioXcel Therapeutics' earnings history.

What price target have analysts set for BTAI?

5 brokerages have issued 1 year price objectives for BioXcel Therapeutics' stock. Their forecasts range from $24.00 to $95.00. On average, they anticipate BioXcel Therapeutics' share price to reach $59.80 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View analysts' price targets for BioXcel Therapeutics.

Has BioXcel Therapeutics been receiving favorable news coverage?

News articles about BTAI stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioXcel Therapeutics earned a news impact score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutBioXcel Therapeutics.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 852,400 shares, an increase of 30.0% from the April 30th total of 655,500 shares. Based on an average daily trading volume, of 700,400 shares, the short-interest ratio is presently 1.2 days. Approximately 8.1% of the company's stock are short sold. View BioXcel Therapeutics' Current Options Chain.

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include Alibaba Group (BABA), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), Editas Medicine (EDIT), Micron Technology (MU), InVitae (NVTA), Tesla (TSLA), Square (SQ) and Cisco Systems (CSCO).

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (3.90%), Artemis Investment Management LLP (3.90%), BlackRock Inc. (2.47%), Driehaus Capital Management LLC (1.49%), Massachusetts Financial Services Co. MA (1.36%) and Nuveen Asset Management LLC (0.76%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View institutional ownership trends for BioXcel Therapeutics.

Which institutional investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Artemis Investment Management LLP, Squarepoint Ops LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., UBS Group AG, Morgan Stanley, and Creative Planning. View insider buying and selling activity for BioXcel Therapeutics.

Which institutional investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Massachusetts Financial Services Co. MA, Nuveen Asset Management LLC, Orbimed Advisors LLC, BlackRock Inc., Federated Hermes Inc., Moody Aldrich Partners LLC, and EAM Global Investors LLC. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta. View insider buying and selling activity for BioXcel Therapeutics.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $46.56.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $940.98 million. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.